Quest Diagnostics Incorporated (DGX): Price and Financial Metrics


Quest Diagnostics Incorporated (DGX): $142.50

0.09 (+0.06%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

DGX POWR Grades


  • DGX scores best on the Quality dimension, with a Quality rank ahead of 93.17% of US stocks.
  • DGX's strongest trending metric is Growth; it's been moving down over the last 51 weeks.
  • DGX ranks lowest in Momentum; there it ranks in the 24th percentile.

DGX Stock Summary

  • With a price/earnings ratio of 7.74, Quest Diagnostics Inc P/E ratio is greater than that of about just 12.74% of stocks in our set with positive earnings.
  • In terms of twelve month growth in earnings before interest and taxes, Quest Diagnostics Inc is reporting a growth rate of 170.68%; that's higher than 87.18% of US stocks.
  • Quest Diagnostics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 16.56%, greater than the shareholder yield of 87.2% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Quest Diagnostics Inc, a group of peers worth examining would be LEA, PKG, STLD, BAH, and ATKR.
  • DGX's SEC filings can be seen here. And to visit Quest Diagnostics Inc's official web site, go to www.questdiagnostics.com.

DGX Valuation Summary

  • In comparison to the median Healthcare stock, DGX's EV/EBIT ratio is 75.09% lower, now standing at 7.3.
  • Over the past 243 months, DGX's price/sales ratio has gone down 0.
  • Over the past 243 months, DGX's price/sales ratio has gone down 0.

Below are key valuation metrics over time for DGX.

Stock Date P/S P/B P/E EV/EBIT
DGX 2021-08-31 1.7 3.2 8.3 7.3
DGX 2021-08-30 1.7 3.1 8.2 7.3
DGX 2021-08-27 1.6 3.1 8.1 7.2
DGX 2021-08-26 1.7 3.1 8.1 7.2
DGX 2021-08-25 1.7 3.1 8.1 7.2
DGX 2021-08-24 1.7 3.1 8.1 7.2

DGX Growth Metrics

  • Its year over year net income to common stockholders growth rate is now at 127.11%.
  • Its 4 year net income to common stockholders growth rate is now at 5.73%.
  • The year over year net cashflow from operations growth rate now stands at 104.86%.
Over the past 30 months, DGX's revenue has gone up $3,527,000,000.

The table below shows DGX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 11,058 2,594 2,247
2021-03-31 10,335 2,489 1,801
2020-12-31 9,437 2,005 1,431
2020-09-30 8,361 1,812 1,105
2020-06-30 7,531 1,249 752
2020-03-31 7,657 1,215 793

DGX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DGX has a Quality Grade of B, ranking ahead of 93.21% of graded US stocks.
  • DGX's asset turnover comes in at 0.805 -- ranking 32nd of 81 Healthcare stocks.
  • SSY, LH, and TDOC are the stocks whose asset turnover ratios are most correlated with DGX.

The table below shows DGX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.805 0.412 0.417
2021-03-31 0.750 0.404 0.340
2020-12-31 0.709 0.385 0.277
2020-09-30 0.643 0.362 0.221
2020-06-30 0.604 0.334 0.162
2020-03-31 0.629 0.339 0.174

DGX Price Target

For more insight on analysts targets of DGX, see our DGX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $157.67 Average Broker Recommendation 1.56 (Moderate Buy)

DGX Stock Price Chart Interactive Chart >

Price chart for DGX

DGX Price/Volume Stats

Current price $142.50 52-week high $160.56
Prev. close $142.41 52-week low $113.36
Day low $142.08 Volume 3,432,200
Day high $143.67 Avg. volume 1,238,522
50-day MA $149.56 Dividend yield 1.74%
200-day MA $134.04 Market Cap 17.41B

Quest Diagnostics Incorporated (DGX) Company Bio


Quest Diagnostics provides diagnostic testing information services in the United States and internationally. The company offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, as well as related services and insights; laboratory testing services for new drugs, vaccines, and medical devices, analytic, on-site prevention, and wellness services, and risk assessment services for the life insurance industry. The company was founded in 1967 and is founded in Madison, New Jersey.


DGX Latest News Stream


Event/Time News Detail
Loading, please wait...

DGX Latest Social Stream


Loading social stream, please wait...

View Full DGX Social Stream

Latest DGX News From Around the Web

Below are the latest news stories about Quest Diagnostics Inc that investors may wish to consider to help them evaluate DGX as an investment opportunity.

DA Authorizes Quest Diagnostics' COVID-19 Collection Materials for Emergency Use

SECAUCUS, N.J., October 15, 2021 /3BL Media/ -- Quest Diagnostics, the world’s leading provider of diagnostic information services, has received FDA emergency use authorization (EUA) for its Quest ...

Yahoo | October 15, 2021

Quest Diagnostics (DGX) Base Arm Recovers, Testing Sales Grow

Quest Diagnostics (DGX) is hopeful about the fact that COVID-19 testing remains critical as employees are returning to the workplace and students to the classroom.

Yahoo | October 15, 2021

Quest Diagnostics (DGX) Expected to Beat Earnings Estimates: Should You Buy?

Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | October 14, 2021

Quest Diagnostics (DGX) Enhances Lab Experience With Facility

Quest Diagnostics (DGX) new facility is fully operational and will empower better health for the patients and clients in the seven states the lab serves.

Yahoo | October 14, 2021

COVID Test Demand to Aid Quest Diagnostics (DGX) Q3 Earnings

In terms of strategic acquisitions, Quest Diagnostics (DGX) is likely to have secured high returns in Q3 from the acquisition of Mercy's outreach laboratory services business.

Yahoo | October 14, 2021

Read More 'DGX' Stories Here

DGX Price Returns

1-mo -7.53%
3-mo 5.04%
6-mo 11.14%
1-year 20.74%
3-year 48.21%
5-year 88.17%
YTD 21.78%
2020 14.11%
2019 31.13%
2018 -13.84%
2017 9.16%
2016 31.90%

DGX Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full DGX Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8577 seconds.